Impact of RTS,S/AS02A and RTS,S/AS01B on genotypes of P. falciparum in adults participating in a malaria vaccine clinical trial

PLoS ONE

Volumn 4, Issue 11, 2009, Pages

  Waitumbi, John N ^a   Anyona, Samuel B ^a   Hunja, Carol W ^a   Kifude, Carolyne M ^a   Polhemus, Mark E ^a   Walsh, Douglas S ^a   Ockenhouse, Chris F ^b   Heppner Jr , D Gray ^b   Leach, Amanda ^c   Lievens, Marc ^c   Ballou, W Ripley ^c,e   Cohen, Joe D ^c   Sutherland, Colin J ^d  

^a KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^c GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^e BILL AND MELINDA GATES FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; IMMUNOLOGICAL ADJUVANT; MALARIA VACCINE; RABIES VACCINE; RTS,S PLUS ASO2A VACCINE; RTS,S PLUS ASO2B VACCINE; UNCLASSIFIED DRUG; RTS,S AS01B VACCINE; RTS,S AS02A VACCINE; RTS,S-AS01B VACCINE; RTS,S-AS02A VACCINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG FORMULATION; DRUG SAFETY; GENE LOCUS; GENOTYPE; HAPLOTYPE; HUMAN; IMMUNOGENICITY; KENYA; MAJOR CLINICAL STUDY; MALARIA; PARASITE ISOLATION; PARASITEMIA; PLASMODIUM FALCIPARUM; TH2 CELL; ADOLESCENT; ADULT; ALLELE; CHEMISTRY; CONTROLLED CLINICAL TRIAL; DNA SEQUENCE; FEMALE; GENETIC POLYMORPHISM; GENETICS; MALE; METABOLISM; PARASITOLOGY; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

PLASMODIUM FALCIPARUM;

ADOLESCENT; ADULT; ALLELES; EPITOPES, T-LYMPHOCYTE; FEMALE; GENOTYPE; HAPLOTYPES; HUMANS; MALARIA; MALARIA VACCINES; MALE; PLASMODIUM FALCIPARUM; POLYMORPHISM, GENETIC; SEQUENCE ANALYSIS, DNA;

EID: 70849110143     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0007849     Document Type: Article

References (34)

1. A single agenda needed for malaria control (2003) Lancet Infect Dis 3: 317.
2. The Global Fund to Fight AIDS Tuberculosis, and Malaria (2006) Funding the Global Fight Against HIV/AIDS, Tuberculosis, and Malaria. Geneva, Switzerland, .
3. Current Grant Commitments and Disbursements of the Global Fund to Fight AIDS, Tuberculosis, and Malaria. The Global Fund to Fight AIDS Web site. http://www.theglobalfund.org/en/funds_raised/commitments. Accessed February 5, 2009.
4. Lengeler C (2004) Insecticide-treated bed nets and curtains for preventing malaria. Cochrane Database Syst Rev 2: CD000363.
5. Ashley EA, White NJ (2005) Artemisinin-based combinations. Curr Opin Infect Dis 18: 531-536.
6. Epstein JE, Giersing B, Mullen G, Moorthy V, Richie TL (2007) Curr Opin Mol Therap 9: 12-24.
7. Ballou WR, Arevalo-Herrera M, Carucci D, Richie TL, Corradin G, et al. (2004) Update on the clinical development of candidate malaria vaccines. Am J Trop Med Hyg 71: 239-247.
8. Heppner DG Jr, Kester KE, Ockenhouse CF, Tornieporth N, Ofori O, et al. (2005) Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: Progress at the Walter Reed Army Institute of Research. Vaccine 23: 2243-2250.
9. Kester KE, McKinney DA, Tornieporth N, Ockenhouse CF, Heppner DG, et al. (2001) Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. J Infect Dis 183: 640-647.
10. Stoute JA, Slaoui M, Heppner DG, Momin P, Kester KE, et al. (1997) A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. N Engl J Med 336: 86-91.
11. A in malaria-naïve adults. Vaccine 25: 5359-66.
12. Kester KE, Cummings JF, Ockenhouse CF, Nielsen R, Hall BT, et al. (2008) Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naïve adults at the Walter Reed Army Institute of Research. Vaccine 26: 2191-202.
13. Kester KE, Cummings JF, Ofori-Anyiam O, Krzych U, Schwenk R, et al. (2009) Randomized, double-blind, Phase 2 trial of falciparum malaria vaccines RTS,S/AS01 and RTS,S/AS02 in malaria-naïve adults; safety, efficacy and immunologic associates of protection. J Infect Dis 200: 337-46.
14. A. Vaccine 24: 6483-6492.
15. Stewart VA, Walsh DS, McGrath SM, Kester KE, Cummings JF, et al. (2006) Cutaneous delayed-type hypersensitivity (DTH) in a multi-formulation comparator trial of the anti-falciparum malaria vaccine candidate RTS,S in rhesus macaques. Vaccine 24: 6493-502.
16. Mettens P, Dubois PM, Demoitié MA, Bayat B, Donner MN, et al. (2007) Improved T cell responses to Plasmodium falciparum circumsporozoite protein in mice and monkeys induced by a novel formulation of RTS,S vaccine antigen. Vaccine 26: 1072-82.
17. B in Adults in a High Malaria Transmission Area. PLoS One 4(7): e6465.
18. A vaccine against Plasmodium falciparum infection and disease in young African children: Randomised controlled trial. Lancet 364: 1411-1420.
19. A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: Single-blind extended follow-up of a randomised controlled trial. Lancet 366: 2012-2018.
20. Aponte JJ, Aide P, Renom M, Mandomando I, Bassat Q, et al. (2007) Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial. Lancet 370: 1543-51.
21. Sacarlal J, Aide P, Aponte JA, Renom M, Leach A, et al. (2009) Long-term safety and efficacy of the RTS,S/AS02A malaria vaccine in Mozambican children. J Inf.Dis 200: 329-36.
22. Abdulla S, Oberholzer R, Juma O, Kubhoja S, Machera F, et al. (2008) Safety and immunogenicity of RTS,S/AS02D Malaria Vaccine in Infants. N Engl J Med 359: 2533-44.
23. Bejon P, Lusingu J, Olotu A, Leach A, Lievens M, et al. (2008) Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med 359: 2521-32.
24. Escalante AA, Grebert HM, Isea R, Goldman IF, Basco L, et al. (2002) A study of genetic diversity in the gene encoding the circumsporozoite protein (CSP) of Plasmodium falciparum from different transmission areas - XVI. Asembo Bay Cohort Project. Mol Biochem Parasitol 125: 83-90.
25. Alloueche A, Milligan P, Conway DJ, Pinder M, Bojang K, et al. (2003) Protective efficacy of the RTS,S/AS02 Plasmodium falciparum malaria vaccine is not strain specific. Am J Trop Med Hyg 68: 97-101.
26. A malaria vaccine does not induce parasite CSP T cell epitope selection and reduces multiplicity of infection. PLoS Clinical Trials 1(1): e5.
27. Snounou G, Zhu X, Siripoon N, Jarra W, Thaithong S, et al. (1999) Biased distribution of msp1 and msp2 allelic variants in Plasmodium falciparum populations in Thailand. Transactions of the Royal Society of Tropical Medicine and Hygiene 93: 369-374.
28. Ord R, Alexander N, Dunyo S, Hallett RL, Jawara M, et al. (2007) Seasonal carriage of pfcrt and pfmdr1 alleles in Gambian Plasmodium falciparum imply reduced fitness of chloroquine-resistant parasites. J Infect Dis 196: 1613-1619.
29. Doolan DL, Saul AJ, Good MF (1992) Geographically restricted heterogeneity of the Plasmodium falciparum circumsporozoite protein: relevance for vaccine development. Infect Immun 60: 675-682.
30. Takala SL, Coulibaly D, Thera MA, Dicko A, Smith DL, et al. (2007) Dynamics of polymorphism in a malaria vaccine antigen at a vaccine-testing site in Mali. PLoS Med 4: e93.
31. Ofosu-Okyere A, Mackinnon MJ, Sowa MP, Koram KA, Nkrumah F, et al. (2001) Novel Plasmodium falciparum clones and rising clone multiplicities are associated with the increase in malaria morbidity in Ghanaian children during the transition into the high transmission season. Parasitology 123: 113-123.
32. Mayor A, Saute F, Aponte JJ, Almeda J, Gomez-Olive FX, et al. (2003) Plasmodium falciparum multiple infections in Mozambique, its relation to other malariological indices and to prospective risk of malaria morbidity. Trop Med Int Health 8: 3-11.
33. Farnert A, Rooth I, Svensson A, Snounou G, Bjorkman A (1999) Complexity of Plasmodium falciparum infections is consistent over time and protects against clinical disease in Tanzanian children. J Infect Dis 179: 989-995.
34. Cortes A, Mellombo M, Benet A, Lorry K, Rare L, et al. (2004) Plasmodium falciparum: Distribution of msp2 genotypes among symptomatic and asymptomatic individuals from the Wosera region of Papua New Guinea. Exp Parasitol 106: 22-29.